- Home
- CHPT vs TBPH Comparison
CHPT vs TBPH Comparison
Compare CHPT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- TBPH
- Stock Information
- Founded
- CHPT 2007
- TBPH 2013
- Country
- CHPT United States
- TBPH United States
- Employees
- CHPT N/A
- TBPH N/A
- Industry
- CHPT Industrial Specialties
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- TBPH Health Care
- Exchange
- CHPT Nasdaq
- TBPH Nasdaq
- Market Cap
- CHPT 483.4M
- TBPH 485.8M
- IPO Year
- CHPT N/A
- TBPH N/A
- Fundamental
- Price
- CHPT $1.24
- TBPH $9.59
- Analyst Decision
- CHPT Hold
- TBPH Buy
- Analyst Count
- CHPT 13
- TBPH 4
- Target Price
- CHPT $2.51
- TBPH $13.75
- AVG Volume (30 Days)
- CHPT 18.6M
- TBPH 217.1K
- Earning Date
- CHPT 12-04-2024
- TBPH 11-12-2024
- Dividend Yield
- CHPT N/A
- TBPH N/A
- EPS Growth
- CHPT N/A
- TBPH N/A
- EPS
- CHPT N/A
- TBPH N/A
- Revenue
- CHPT $431,026,000.00
- TBPH $63,192,000.00
- Revenue This Year
- CHPT N/A
- TBPH $11.41
- Revenue Next Year
- CHPT $15.02
- TBPH $37.36
- P/E Ratio
- CHPT N/A
- TBPH N/A
- Revenue Growth
- CHPT N/A
- TBPH 15.93
- 52 Week Low
- CHPT $1.05
- TBPH $7.44
- 52 Week High
- CHPT $2.68
- TBPH $11.71
- Technical
- Relative Strength Index (RSI)
- CHPT 51.77
- TBPH 50.13
- Support Level
- CHPT $1.13
- TBPH $9.62
- Resistance Level
- CHPT $1.30
- TBPH $10.08
- Average True Range (ATR)
- CHPT 0.11
- TBPH 0.31
- MACD
- CHPT -0.00
- TBPH -0.06
- Stochastic Oscillator
- CHPT 32.05
- TBPH 25.00
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).